Purpose: To evaluate the therapeutic effect of intravitreal bevacizumab in patients with uveitis-associated choroidal/retinal neovascularization.
Methods: Two female patients (40 years, 15 years) with posterior uveitis, (one presumed ocular sarcoidosis, one lupus) were evaluated for neovascularization of the posterior segment. Both patients were given a single dose of 1.25 mg intravitreal bevacizumab.
Results: Significant anatomical and functional recovery was evident in both patients within a few weeks.
Conclusion: In selected uveitic patients, bevacizumab may be an option for managing neovascularization.